469 - 480 of 7685 results
0.25 CME CREDIT

GLP-1 Receptor Agonists: A Cardiology Perspective (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

In this podcast, cardiologist Ty Gluckman will take a deep dive into the cardiology benefits of glucagon like peptide-1 receptor agonists (GLP-1 RA). He will review the clinical trial data which has resulted in GLP-1 RA incorporation into guidelines, which address patients who have both diabetes and atherosclerotic cardiovascular disease. Dr. Gluckman will bring the perspective of a cardiologist into the discussion of these agents with emerging significance in cardiovascular risk reduction.


0.5 CME CREDIT

COVID-19 Panel Discussion

0.50 CME
0.50 AANP

Join an expert panel hosted by Pamela Kushner, MD with infectious disease experts Paul Sax, MD and Daniel Solomon, MD as they answer your COVID-19 questions. In addition to answering live questions from the audience, faculty will share their clinical experiences, and discuss the most relevant updates in the literature and current recommendations regarding COVID-19. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 06/26/2020 and they are subject to change as new information is published.


1 CME CREDIT

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.


1 CME CREDIT

This session will shine a light on health disparities in the U.S. and ways to overcome them by embracing diversity, combatting bias, and employing cultural competency to improve patient-provider communication. These valuable tips can ultimately enhance healthcare for your patients of all races, ethnicities, and cultures. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 06/26/2020 and they are subject to change as new information is published.


1 CME CREDIT

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.


PrimaryCareNOW: Recorded Live on June 26, 2020

2.50 CME/MOC
2.50 AANP | 0.75 Pharmacology


Primary Care Pulse: Live on November 17, 2020

Pri-Med's new weekly CME/CE web series, Primary Care Pulse, features live conversations about timely topics and concerns facing primary care clinicians.


0.5 CME CREDIT

COVID-19 in the Office: Outpatient Management

Guest: Paul E. Sax, MDMusic Credit: Richard Onorato

0.50 CME

So much has changed concerning COVID-19 management, but few interventions are clearly beneficial in the outpatient management of patients. This podcast will try to answer some of the common questions community based providers have about handling their patients’ illness.


0.5 CME CREDIT

Treating chronic pain in older individuals and balancing analgesia and adverse effects in this population, which is often afflicted with multiple comorbidities, is challenging. This program reviews the assessment and nonpharmacologic treatment of chronic pain in patients aged 65 years and older. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).


1.5 CME CREDITS

Strategies for Effective Pain Management: The Basics

1.50 CME/MOC
1.50 AANP | 0.38 Pharmacology

This activity will discuss the epidemiology and pathophysiology of acute and chronic pain, patient assessment, assessment of risk for opioid-related aberrant behaviors, nonpharmacologic approaches to pain management, and non-opioid analgesics. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 3/19/2020 and they are subject to change as new information is published.


0.35 CME CREDIT

Pain Points: Nonopioid Pharmacologic Options in Older Adults

0.25 CME/MOC
0.35 AANP | 0.23 Pharmacology

Nonopioid therapy is an important tool for the treatment of chronic pain. But agents differ as to efficacy and safety in older patients. This program reviews the different classes of nonopioid medications, their efficacy in different types of pain, and their use in older patients. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).